 |
|
 |
 |

Home > Company Index > Drugs > Drug Delivery > Maxygen, Inc.
 |
Maxygen, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Techs, telcos boost eurostocks, Pirelli pounded Jul 30 2001 08:31 AM PDT
Maxygen sees narrower-than-expected '01 loss Jul 12 2001 01:40 PM PDT
> More WIRE STORIES about this company
PROFILE |
 |
With technology that sounds like it's straight out of a casino supply house, Maxygen is gambling on directed molecular evolution. Its DNAShuffling recombination technology and MaxyScan screening systems are used to develop genes for commercial use. Its MolecularBreeding technology combines biotech advances with traditional breeding techniques, mimicking natural evolution processes to make products for vaccines, genetically engineered crops, and new energy sources. Maxygen has some 40 products in its pipeline and has development alliances with such companies as Novo Nordisk, DuPont's Pioneer Hi-Bred International, and Syngenta. GlaxoSmithKline owns about 20% of the firm.
COMPETITION |
 |
CV Therapeutics, Inc. (CVTX)
Enzo Biochem, Inc. (ENZ)
Lynx Therapeutics, Inc. (LYNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
2000 Sales (mil.): 24.50
1-Yr. Sales Growth: 75.0%
Employees: 256
Revenue per employee: $95,703.12
KEY PEOPLE |
 |
Russell J. Howard
CEO
Lawrence Briscoe
CFO
CONTACT INFO |
 |
515 Galveston Dr.
Redwood City, CA 94063
US
Phone: 650-298-5300
Fax: 650-364-2715
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |